Citations

Clear

10 citation(s) found for "Brown, Andrew".

Stopping Spin at the Source: Learning From an Example in Obesity
Brown, Andrew W. , Jensen, Michael D. , Allison, David B. , Jensen, Michael , Allison, David B

Mayo Clinic

Obesity | April 12, 2026 | Volume: 34 | Issue: 6 | Pages: 1183-1186

10.1002/oby.70159 | PMID 41967833 Get It

Fracture nonunions
Le, Vu , Jones, Clifford B. , Working, Zachary M. , Duda, Georg N. , Evans, Andrew R. , Evans, Christopher, Evans, Chris

Mayo Clinic

OTA International | October 6, 2025 | Volume: 8 | Issue: 5S | Pages: No page available

10.1097/oi9.0000000000000441 | PMID 41054623 Get It

Abstract The Fracture Nonunion Symposium presented at the 2024 Orthopaedic Trauma Association Basic Science Focus Forum featured invited speakers who discussed current perspectives on this topic. Clinical approaches, diagnostic advancements, basic science perspectives, and novel treatment strategies were discussed. This symposium was curated to highlight this common and challenging clinical problem faced by orthopaedic and musculoskeletal practitioners from around the globe.
Novel risk loci in LGI1-antibody encephalitis: genome-wide association study discovery and validation cohorts
Elliott, Katherine S. , Gilbert, Edmund , Harper, Andrew R. , Sempere, Vicente Peris, Pinto, Anne‐Laurie , Rayner, N. William, Mentzer, Alexander J. , Delanty, Norman, Picard, Géraldine , Titulaer, Maarten J. , Kuhlenbäeumer, Gregor, Mignot, Emmanuel , Cavelleri, Gianpiero L, Irani, Sarosh R. , Cavalleri, Gianpiero L. , Mentzer, Alexander J , Handel, Adam , Melzer, Nico , Lee, Soon-Tae , Leypoldt, Frank , Honnorat, Jérôme , Mignot, Emmanuel , Irani, Sarosh R , Cavalleri, Gianpiero L , Titulaer, Maarten J , Binks, Sophie , Muñiz‐Castrillo, Sergio , Araujo, Tânia Kawasaki de , Brown, Andrew , Chong, Amanda Yoon-Yee , Band, Gavin , Costantino, Félicie , Rogemond, Véronique , Handel, Adam E. , Lee, Soon‐Tae , Honnorat, Jérôme , Knight, Julian Charles

Mayo Clinic

Brain | October 24, 2024 | Volume: 148 | Issue: 3 | Pages: 737-745

10.1093/brain/awae349 | PMID 39454566 Get It

Abstract Encephalitis with antibodies to leucine-rich glioma-inactivated 1 (LGI1-Ab-E) is a common form of autoimmune encephalitis, presenting with seizures and neuropsychiatric changes, predominantly in older males. More than 90% of patients carry the human leukocyte antigen (HLA) class II allele, HLA-DRB1*07:01. However, this is also present in 25% of healthy controls. Therefore, we hypothesized the presence of additional genetic predispositions. In this genome-wide association study and meta-analysis, we studied a discovery cohort of 131 French LGI1-Ab-E and a validation cohort of 126 American, British and Irish LGI1-Ab-E patients, ancestry-matched to 2613 and 2538 European controls, respectively. Outside the known major HLA signal, we found two single nucleotide polymorphisms at genome-wide significance (P < 5 × 10−8), implicating PTPRD, a protein tyrosine phosphatase, and LINC00670, a non-protein coding RNA gene. Meta-analysis defined four additional non-HLA loci, including the protein coding COBL gene. Polygenic risk scores with and without HLA variants proposed a contribution of non-HLA loci. In silico network analyses suggested LGI1 and PTPRD-mediated interactions via the established receptors of LGI1, ADAM22 and ADAM23. Our results identify new genetic loci in LGI1-Ab-E. These findings present opportunities for mechanistic studies and offer potential markers of susceptibility, prognostics and therapeutic responses.
The effect of plasma exchange on serum levels of lacosamide: A case report
Peters, Bradley J. , Brown, Andrew E. , Thornton, Nathaniel M, Chalmers, Sarah , Chalmers, Sarah J, Thornton, Nathaniel M, Winters, Jeffrey L.

Mayo Clinic

American Journal of Health-System Pharmacy | September 15, 2023 | Volume: 80 | Issue: 24 | Pages: 1781-1786

10.1093/ajhp/zxad224 | PMID 37712141 Get It

Abstract Purpose We describe the case of a 22-year-old male who developed thyroid storm necessitating therapeutic plasma exchange (TPE). The patient’s past medical history was complicated by epilepsy, for which he took lacosamide. Little evidence was available to guide lacosamide dosing during TPE. Because of an exacerbation of the patient’s underlying epilepsy in the context of the thyroid storm, we conducted therapeutic medication monitoring of lacosamide concentrations to guide management. Summary We arranged for measurement of the lacosamide concentration immediately before TPE (5.1 μg/mL) and 2.5 hours after the initial measurement (3.4 μg/mL) to determine the amount of lacosamide removed by TPE. Utilizing population pharmacokinetic parameters, we calculated the expected concentration and compared this to the measured concentration. The difference between these values was used to determine the percentage removed via TPE compared to the expected post-TPE concentration. We found that one TPE session removed an additional 20% of serum lacosamide. Conclusion TPE appeared to remove an additional 20% of lacosamide when compared to the expected post-TPE concentration.
Tenascin‐R Autoimmunity: Isolated Tremor Reversed with Immunotherapy
Yang, Binxia , McKeon, Andrew , Ahlskog, J. Eric , Tipton, Philip W. , Guo, Yong , Lucchinetti, Claudia F. , Pittock, Sean J. , Ζεκερίδου, Αναστασία , Brown, Andrew E. , Pittock, S J , Brown, Andrew , McKeon, Andrew , Tipton, Philip W , Lucchinetti, Claudia F , Zekeridou, Anastasia , Yang, Binxia , Brown, Andrew D.

Mayo Clinic

Annals of Neurology | June 28, 2023 | Volume: 94 | Issue: 3 | Pages: 502-507

10.1002/ana.26730 | PMID 37370243 Get It

Autoimmune movement disorders are increasingly recognized, but isolated tremor is extremely rare. We describe a 70‐year‐old male with rapidly progressive, severe postural and intention tremor and weight loss. His cerebrospinal fluid was inflammatory and harbored a neural tissue‐restricted antibody. The autoantigen was identified by immunoprecipitation and mass spectrometry and confirmed by antigen‐specific assays to be specific for tenascin‐R. He was investigated for cancer and diagnosed with follicular lymphoma that expressed tenascin‐R suggesting a paraneoplastic origin; cancer treatment and immunotherapy led to complete recovery. With this individualized patient approach and antibody discovery, we expand the spectrum of antibodies accompanying autoimmune hyperkinetic movement disorders. ANN NEUROL 2023;94:502–507
TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis
Kassab, Ihab , Massani, Marco , Townsend, Whitney , Singal, Amit G. , Moreno-Luna, Laura E., Roberts, Lewis R. , Chen, Vincent , Parikh, Neehar D. , Singal, Amit , Moreno-Luna, Laura, Parikh, Neehar D , Roberts, Lewis R , Chen, V L , Brown, Andrew M K , Soydal, Çiğdem

Mayo Clinic

Cancer Medicine | August 9, 2022 | Volume: 12 | Issue: 3 | Pages: 2590-2599

10.1002/cam4.5125 | PMID 35943116 Get It

AbstractBackgroundTransarterial radioembolization (TARE) is increasingly used as an alternative to transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC). We aimed to perform an overall and individual patient data (IPD) meta‐analysis of studies comparing TACE and TARE.MethodsWe performed a systematic literature search using pre‐specified keywords with the aid of an informationist for articles from inception to 3/2020. The primary endpoint was overall survival (OS), and the secondary endpoint was time to progression (TTP).ResultsSeventeen studies met inclusion criteria with 2465 unique patients, with one randomized trial, 4 prospective studies and 12 retrospective studies. Barcelona Clinic Liver Cancer (BCLC) stage B (42.8%) was the most common stage followed by BCLC A (30.3%) and BCLC C (29.0%). There was no difference in OS between the two modalities (−0.55 months, 95% CI −1.95 to 3.05). In three studies with available TTP data, TARE resulted in a longer TTP than TACE (mean TTP 17.5 vs. 9.8 months; mean TTP difference 4.8 months, 95% CI 1.3–8.3 months). IPD‐level meta‐analysis of 311 patients from three studies showed no difference in overall OS between the two modalities including among subgroups stratified by tumor stage and liver function. Limitations of the current literature include inconsistent length of follow‐up, inconsistency in response criteria, and safety reporting.ConclusionsCurrent data suggest TARE provides significantly longer TTP than TACE, although the two treatments do not significantly differ in terms of OS. Given limitations of the current data, there is rationale for prospective studies comparing these modalities.
Video quality using outpatient smartphone videos in epilepsy: Results from the OSmartViE study
Tatum, William O. , Acton, Emily K. , LaFrance, W. Curt , Duckrow, Robert B., Blum, Andrew S. , Hixson, John , Drazkowski, Joe, Cascino, Gregory D. , Collaborators, The OSmartViE, Acton, Emily K , LaFrance, W Curt , Hirsch, Lawrence J. , Gelfand, Michael , Chen, David , Benbadis, Selim R. , Collaborators, The OSmartViE

Mayo Clinic

European Journal of Neurology | January 19, 2021 | Volume: 28 | Issue: 5 | Pages: 1453-1462

10.1111/ene.14744 | PMID 33465822 Get It

Abstract Background and purpose The aim of this study was to evaluate the quality of smartphone videos (SVs) of neurologic events in adult epilepsy outpatients. The use of home video recording in patients with neurological disease states is increasing. Experts interpretation of outpatient smartphone videos of seizures and neurological events has demonstrated similar diagnostic accuracy to inpatient video‐electroencephalography (EEG) monitoring. Methods A prospective, multicenter cohort study was conducted to evaluate SV quality in patients with paroxysmal neurologic events from August 15, 2015 through August 31, 2018. Epileptic seizures (ESs), psychogenic nonepileptic attacks (PNEAs), and physiologic nonepileptic events (PhysNEEs) were confirmed by video‐EEG monitoring. Experts and senior neurology residents blindly viewed cloud‐based SVs without clinical information. Quality ratings with regard to technical and operator‐driven metrics were provided in responses to a survey. Results Forty‐four patients (31 women, age 45.1 years [ r = 20–82]) were included and 530 SVs were viewed by a mean of seven experts and six residents; one video per patient was reviewed for a mean of 133.8 s ( r = 9–543). In all, 30 patients had PNEAs, 11 had ESs, and three had PhysNEEs. Quality was suitable in 70.8% of SVs (375/530 total views), with 36/44 (81.8%) patient SVs rated as adequate by the majority of reviewers. Accuracy improved with the presence of convulsive features from 72.4% to 98.2% in ESs and from 71.1% to 95.7% in PNEAs. An accurate diagnosis was given by all reviewers (100%) in 11/44 SVs (all PNEAs). Audio was rated as good by 86.2% of reviewers for these SVs compared with 75.4% for the remaining SVs ( p = 0.01). Lighting was better in SVs associated with high accuracy ( p = 0.06), but clarity was not ( p = 0.59). Poor video quality yielded unknown diagnoses in 24.2% of the SVs reviewed. Features hindering diagnosis were limited interactivity, restricted field of view and short video duration. Conclusions Smartphone video quality is adequate for clinical interpretation in the majority of patients with paroxysmal neurologic events. Quality can be optimized by encouraging interactivity with the patient, adequate duration of the SV, and enlarged field of view during videography. Quality limitations were primarily operational though accuracy remained for SV review of ESs and PNEAs.
2018 International Consensus Meeting on Musculoskeletal Infection: Research Priorities from the General Assembly Questions
Schwarz, Edward M. , Gehrke, Thorsten , Aiyer, Amiethab A. , Battenberg, Andrew K. , Brown, Scot , Callaghan, John J. , Egol, Kenneth A. , Garrigues, Grant E. , Ghert, Michelle , Goswami, Karan , Hammound, Sommer, McLaren, A. C. , Mont, Michael A. , Namdari, Surena , Obremskey, William T. , O’Toole, Robert V. , Raikin, Steven M. , Restrepo, Camilo , Ricciardi, Benjamin F. , Saeed, Kordo , Shohat, Noam , Tan, Timothy L. , Thirukumaran, Caroline P. , Winters, Brian S., Sanchez-Sotelo, Joaquin, Schwarz, Edward M , Parvizi, Javad , Gehrke, Thorsten A. , Çıtak, Mustafa , Green, Andrew , Kates, Stephen L. , Sánchez‐Sotelo, Joaquín

Mayo Clinic

Journal of Orthopaedic Research | April 12, 2019 | Volume: 37 | Issue: 5 | Pages: 997-1006

10.1002/jor.24293 | PMID 30977537 Get It

ABSTRACT Musculoskeletal infections (MSKI) remain the bane of orthopedic surgery, and result in grievous illness and inordinate costs that threaten healthcare systems. As prevention, diagnosis, and treatment has remained largely unchanged over the last 50 years, a 2nd International Consensus Meeting on Musculoskeletal Infection (ICM 2018, https://icmphilly.com ) was completed. Questions pertaining to all areas of MSKI were extensively researched to prepare recommendations, which were discussed and voted on by the delegates using the Delphi methodology. The questions, including the General Assembly (GA) results, have been published ( GA questions ). However, as critical outcomes include: (i) incidence and cost data that substantiate the problems, and (ii) establishment of research priorities; an ICM 2018 research workgroup (RW) was assembled to accomplish these tasks. Here, we present the result of the RW consensus on the current and projected incidence of infection, and the costs per patient, for all orthopedic subspecialties, which range from 0.1% to 30%, and $17,000 to $150,000. The RW also identified the most important research questions. The Delphi methodology was utilized to initially derive four objective criteria to define a subset of the 164 GA questions that are high priority for future research. Thirty‐eight questions (23% of all GA questions) achieved the requisite > 70% agreement vote, and are highlighted in this Consensus article within six thematic categories: acute versus chronic infection, host immunity, antibiotics, diagnosis, research caveats, and modifiable factors. Finally, the RW emphasizes that without appropriate funding to address these high priority research questions, a 3rd ICM on MSKI to address similar issues at greater cost is inevitable.
Evaluating the Context-Dependent Effect of Family History of Stroke in a Genome Scan for Hypertension
Morrison, Alanna C. , Kardia, Sharon L. R., Boerwinkle, Eric , Brown, Andrew , Turner, Stephen T. , Morrison, Alanna C

Mayo Clinic

Stroke | May 1, 2003 | Volume: 34 | Issue: 5 | Pages: 1170-1175

10.1161/01.str.0000068780.47411.16 | PMID 12714704 Get It

Background and Purpose— Hypertension is an important risk factor for stroke, and the 2 diseases may share susceptibility genes in common. We sought to identify genomic regions influencing susceptibility to both hypertension and stroke. Subjects and Methods— Genome-wide linkage scans were performed in samples of 338 white and 265 black hypertensive sibships recruited by the Genetic Epidemiology Network of Arteriopathy Study of the NHLBI Family Blood Pressure Program (FBPP). The hypertensive sibships were stratified by positive (+FH) or negative (−FH) family history of stroke. Genome-wide scans were repeated in each stratum, and the results were compared within each ethnic group by a regression-based analysis of heterogeneity. Results— In whites, the best evidence for linkage was found on chromosome 16 in the unstratified sample of hypertensive sibpairs (logarithm of odds [LOD]=1.85 at 71 cM). In blacks, the best evidence for linkage was found on chromosome 2 in the unstratified sample of hypertensive sibpairs (LOD=1.95 at 230 cM). Additional evidence for linkage (LOD ≥1.5) was observed among white hypertensive sibpairs with a −FH on chromosome 13 and among black hypertensive sibpairs with a +FH of stroke on chromosome 19. Conclusions— Significant evidence for linkage heterogeneity among hypertensive sibpairs stratified by family history of stroke suggests the presence of genes influencing susceptibility to both hypertension and stroke on chromosomes 13 (whites) and 19 (blacks). Although no significant evidence of heterogeneity was observed on chromosome 16 in whites and chromosome 2 in blacks, these chromosomes do provide evidence of linkage to hypertension.